Viewpoint: Adapting to new international tuberculosis treatment standards with medication monitors and DOT given selectively

Tropical Medicine and International Health

Volumn 12, Issue 11, 2007, Pages 1302-1308

  Moulding, Thomas S ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

DOT; Medication monitors; Self administered treatment; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; ANTIRETROVIRUS AGENT; ISONIAZID; RIFAMPICIN; THIOACETAZONE;

DISEASE TREATMENT; DRUG RESISTANCE; HEALTH CARE; HEALTH SERVICES; PUBLIC HEALTH; TUBERCULOSIS;

ACCURACY; CLINICAL TRIAL; DIRECTLY OBSERVED THERAPY; DRUG COST; DRUG MONITORING; DRUG SELF ADMINISTRATION; HEALTH CARE FACILITY; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RECORD; MULTIDRUG RESISTANCE; PATIENT ATTITUDE; PATIENT COUNSELING; PATIENT REFERRAL; PHARMACIST; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; REVIEW; SOCIAL WELFARE; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DELIVERY OF HEALTH CARE; DIRECTLY OBSERVED THERAPY; DRUG MONITORING; HUMANS; PATIENT COMPLIANCE; SELF ADMINISTRATION; TUBERCULOSIS;

EID: 36549063525     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2007.01920.x     Document Type: Review

References (48)

1. Aardex Ltd. (2007) Zug Switzerland. Available at: http://www.aardex.ch, accessed on 24 March 2007.
2. Blomberg B, Spinaci S, Fourie B Laing R (2001) The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bulletin of World Health Organization 79, 61 68.
3. Certus International Inc (2007) Chesterfield, Missouri, USA. Available at: http://www.certusintl.com/services_compliance.htm, accessed on 24 March 2007.
4. Connolly C, Davies GR Wilkinson D (1999) Who fails to complete treatment? Temporal trends and risk factors for treatment interruption in a community-based directly observed therapy programme in a rural district of South Africa International Journal of Tuberculosis and Lung Disease 3, 1081 1087.
5. Cypak Inc. (2007) Stockholm, Sweden. Available at: http://www.cypak.com/ digital.php?p=apps&s=digital (accessed on 7 Oct 2007).
6. Davies GR, Pillay M, Sturm AW Wilkinson D (1999) Emergence of multidrug-resistant tuberculosis in a community-based directly observed programme in rural South Africa. International Journal of Tuberculosis and Lung Disease 3, 795 804.
7. Frieden T Sbarbaro JA (2002) The slippery slope to sloppy DOTS. International Journal of Tuberculosis and Lung Disease 6, 371 372.
8. Information Mediary Inc. (2007) Ottawa, Ontario, Canada. Available at: http://www.informationmediary.com/index.shtml, accessed on 24 March 2007.
9. Khan MA, Walley JD, Witter SN, Imran A Safdar N (2002) Costs and cost effectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan. Health Policy Plan 17, 178 186.
10. Kironde S Klaasen S (2002) What motivates lay volunteers in high burden, but resource-limited tuberculosis control programs? Perceptions from the Northern Cape province of South Africa. International Journal of Tuberculosis and Lung Disease 6, 104 110.
11. Li J, Munsiff SS, Driver CR Sackoff J (2005) Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clinical Infectious Diseases 41, 83 91.
12. Lienhardt C Ogden JA (2004) Tuberculosis control in resource-poor countries: have we reached the limits of the universal paradigm? Tropical Medicine and International Health 9, 833 841.
13. Lonnroth K, Lambregts K, Nhien DT, Quy HT Diwan VK (2000) Private pharmacies and tuberculosis control: a survey of case detection skills and reported anti-tuberculosis drug dispensing in private pharmacies in Ho Chi Minh City, Vietnam. International Journal of Tuberculosis and Lung Disease 4, 1052 1059.
14. Lonnroth K, Uplekar M, Arora VK et al. (2004) Public-private mix for DOTS implementation: what makes it work? Bulletin World Health Organization 82, 580 586.
15. Meijnen S, Weismuller MM, Claessens NJ, Kwanjana JH, Salaniponi FM Harries AD (2002) Outcome of patients with tuberculosis who transfer between reporting units in Malawi. International Journal of Tuberculosis and Lung Disease 6, 666 671.
16. Menzies D, Dion MJ, Francis D et al. (2005) In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection. International Journal of Tuberculosis and Lung Disease 9, 1343 1348.
17. Miller LG, Liu H, Hays RD et al. (2002) How well do clinicians estimate patients' adherence to combination antiretroviral therapy? Journal of General Internal Medicine 17, 1 11.
18. Moulding TS (1962) Proposal for a time-recording pill dispenser as a method of studying and supervising the self-administration of drugs. American Review of Respiratory Diseases 85, 754 757.
19. Moulding TS (1979a) The unrealized potential of the medication monitor. Clinical Pharmacology and Therapeutics 25, 131 136.
20. Moulding TS (1979b) The medication monitor for treating tuberculosis in the developing countries. Tropical Doctor 9, 106 109.
21. Moulding TS Caymittes M (2002) Managing medication compliance of tuberculosis patients in Haiti with medication monitors. International Journal of Tuberculosis and Lung Disorders 6, 313 319.
22. Moulding TS Ellis D (2007) Compliance monitors: status of development and potential for expanding effective TB treatment programs. Available at: http://www.medicationmonitors.net, accessed on 18 April 2007.
23. Moulding T, Knight SJ Jr. Colson JB (1967) Vertical pill-calendar dispenser and medication monitor for improving the self-administration of drugs. Tubercle 48, 32 37.
24. Moulding T, Onstad GD Sbarbaro JA (1970) Supervision of outpatient drug therapy with the medication monitor. Annals of Internal Medicine 73, 559 564.
25. Moulding TS, Le HQ, Rikleen D Davidson P (2004) Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin. International Journal of Tuberculosis and Lung Disease 8, 743 748.
26. Nettles RE, Mazo D, Alwood K et al. (2004) Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clinical Infectious Diseases 38, 731 736.
27. Newell JN, Baral SC, Pande SB, Bam DS Malla P (2006) Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial. Lancet 367, 903 909.
28. Paterson DL, Swindells S, Mohr J et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infections. Annals of Internal Medicine 133, 21 30.
29. Pungrassami P, Johnson SP, Chongsuvivatwong V et al. (2002) Practice of directly observed treatment (DOT) for tuberculosis in southern Thailand: comparison between different types of DOT observers. International Journal of Tuberculosis and Lung Disease 6, 389 395.
30. Raviglione MC Pio A (2002) Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet 359, 775 780.
31. Raviglione MC Smith IM (2007) XDR tuberculosis - implications for global public health. New England Journal of Medicine 15, 656 659.
32. Rusen ID, Aid-Khalid N Alarcon E (2007) Cochrane systematic review of directly observed therapy for treating tuberculosis - good analysis of the wrong outcome. International Journal of Tuberculosis and Lung Disease 11, 120 121.
33. Saltini C (2006) Schedule or dosage? The need to perfect intermittent regimens for tuberculosis American Journal of Respiratory and Critical Care Medicine 174, 1067 1068.
34. Simpill Inc. (2007) CapeTown, South Africa. Available at: http://www.on-cue.co.za/, accessed on 24 March 2007.
35. Sumartojo E (1993) When tuberculosis treatment fails. A social behavioral account of patient adherence. American Review of Respiratory Diseases 147, 1311 1320.
36. Thiam S, LeFevre AM, Hane F et al. (2007) Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. Journal of the American Medical Association 297, 380 386.
37. Thomas A, Gopi PG, Santha T et al. (2005) Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. International Journal of Tuberculosis and Lung Disease 9, 556 561.
38. Tuberculosis Coalition for Technical Assistance (2006) International Standards for Tuberculosis Care (ISTC). Tuberculosis Coalition for Technical Assistance, The Hague.
39. Uplekar M, Pathania V Raviglione M (2001) Private practitioners and public health: weak links in tuberculosis control. Lancet 358, 912 916.
40. Volmink J Garner P (2006) Directly observed therapy for treating tuberculosis. Cochrane Database Syst Review (April 19) 2, CD003343.
41. Walley JD, Khan MA, Newell JN Khan MH (2001) Effectiveness of the direct observation component of DOTS for tuberculosis: a randomized controlled trial in Pakistan. Lancet 357, 664 669.
42. WHO (1994) Global Tuberculosis Programme: Framework for Effective TB Control. WHO, Geneva WHO/TB/94.179.
43. WHO (2003a) Treatment of Tuberculosis: Guidelines for National Programmes, 3rd edn. WHO, Geneva WHO/CDS/TB/2003.313.
44. WHO (2003b) Community Contribution to TB Care Practice and Policy. WHO, Geneva WHO/CDS/TB/2003.312.
45. WHO (2006) The STOP TB Strategy. WHO/HTM/STB/2006.37.
46. WHO (2007) Global Tuberculosis Control: Surveillance, Planning, Financing: WHO Report. WHO/HTM/TB/2007/376.
47. Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ Tatley M (1998) Randomized controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 352, 1340 1343.
48. Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ Tatley M (2000) A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis. International Journal of Tuberculosis and Lung Disorders 4, 550 554.